Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.

DOI:10.1016/S1470-2045(15)00613-0
作者：M. Cristofanilli,?N. Turner,?I. Bondarenko,?J. Ro,?S. Im,?N. Masuda,?M. Colleoni,?A. DeMichele,?S. Loi,?S. Verma,?H. Iwata,?N. Harbeck,?Ke Zhang,?K. Theall,?Yuqiu Jiang,?C. H. Bartlett,?M. Koehler,?D.
文献类型：期刊论文
补充材料：只需要正文